Quick Biology

What Quick Biology does

Quick Biology Inc. is a CLIA-certified, CAP-accredited genomics service provider founded in 2015 and headquartered in Monrovia, California (relocated from Pasadena in 2022). The company operates as a high-throughput genomic center serving three primary customer segments: academic and government research institutions, clinical diagnostic providers, and biopharmaceutical companies. Its service portfolio spans next-generation sequencing (RNA-seq, whole exome sequencing, whole genome sequencing, ATAC-seq, single-cell RNA-seq, ChIP-seq, miRNA-seq), clinical molecular diagnostics (Non-Invasive Prenatal Testing, a 127-gene Full Comprehensive Cancer Panel, NGS-based Liquid Biopsy, QuickPathgen pathogen detection), and functional genomics screening products under the 100-QuickPath brand (PCR Arrays, siRNA Arrays, Drug Arrays, Antibody Arrays).

The company's technology stack is built on multiple Illumina platforms (NovaSeq 6000, NovaSeq X, HiSeq X Ten, NextSeq) supplemented by 10x Genomics Chromium for single-cell work and Oxford Nanopore for third-generation sequencing. Bioinformatics pipelines support standard assay types with machine learning integrations for splice variant detection (92% mean precision), variant prioritization (40% precision lift over classical methods), and pharmacogenomics predictions (0.91 AUC). Proprietary assets include the registered QuickPathgen pathogen identification method and the trademarked 100-QuickPath array product family. Quality metrics include >80X average exome coverage for WES samples and 99.86-99.97% mapped reads.

The revenue model is primarily project-based professional services for NGS and clinical diagnostics, complemented by unit-priced catalog products ($259-$289 per array) and quote-based pricing for custom NGS projects with 3-4 week standard turnaround. Go-to-market is sales-led through direct website quote requests with 24-hour response, supplemented by a strategic partnership with Fulgent for capacity expansion and full-scale sequencing service delivery. Notable customers include City of Hope, UCLA, Cedars-Sinai, Caltech, NIH, USDA, and Hartnell College, with testimonials spanning the US, Italy, New Zealand, Colombia, Poland, Ireland, Czechia, and Portugal, indicating active international service delivery from a single California facility.

Name

Quick Biology

Legal name

Quick Biology Inc.

Website

https://quickbiology.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Quick Biology Inc. is a CLIA-certified, CAP-accredited genomics service provider offering next-generation sequencing, clinical molecular diagnostics, and functional genomics array products for academic researchers, healthcare providers, and biopharmaceutical companies globally.

Ownership category

akta.pro rank

Product category

Genomics Services and Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

• Next-generation sequencing services
• Molecular diagnostics
• Clinical genomics
• Bioinformatics analysis
• Functional genomics arrays

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. NGS Services: Core revenue from next-generation sequencing services including RNA sequencing, whole exome sequencing, whole genome sequencing, ATAC sequencing, single-cell RNA sequencing, ChIP sequencing, and associated bioinformatics analysis
2. Clinical Diagnostics: CLIA-certified molecular diagnostic services including Non-Invasive Prenatal Test (NIPT), Cancer Panel, Liquid Biopsy, and Diagnosis of Unknown Diseases
3. Assay Products: Sale of 100-QuickPath array products including PCR Arrays, siRNA Arrays, and Drug Arrays for research use
4. Assay Development Services: Custom assay development and regulatory affairs support for biopharmaceutical clients

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Quick Biology is a CLIA- and CAP-certified genomic center that delivers next-generation sequencing (NGS) services including RNA-seq, whole exome sequencing, whole genome sequencing, ATAC-seq, single-cell RNA-seq, and ChIP-seq, paired with integrated bioinformatics analysis. The company also provides CLIA-certified clinical diagnostics (NIPT, hereditary cancer panels, liquid biopsy, QuickPathgen pathogen detection) and sells 100-QuickPath functional validation array products (PCR, siRNA, drug, antibody arrays) for research use.

Product overview

Quick Biology is a CLIA- and CAP-certified genomics service provider offering a comprehensive portfolio of NGS-based services and molecular diagnostics. The core offerings include next-generation sequencing services (RNA-seq, Whole Exome Sequencing, Whole Genome Sequencing, ATAC-seq, Single Cell RNA-seq, and ChIP-seq) paired with integrated bioinformatics analysis. The company also provides specialized assay products including the 100-QuickPath family (Drug Arrays, siRNA Arrays, PCR Arrays, Antibody Arrays) for functional genomics screening. Clinical diagnostics include Non-Invasive Prenatal Testing, Full Comprehensive Cancer Panel (127 genes), Liquid Biopsy for cancer monitoring, and QuickPathgen for unknown disease diagnosis. All services are supported by machine learning-enhanced bioinformatics pipelines.

Differentiator

Problem solved

Functional benefit

Brands

• 100-QuickPath PCR Arrays: PCR array kits for profiling gene expression in 100 pathways for gene function studies
• 100-QuickPath siRNA Arrays
• 100-QuickPath Drug Arrays
• QuickPathgen

Products and services

• RNA Sequencing (RNA-seq) Next-generation transcriptome sequencing service that enables rapid profiling and deep investigation of RNA, including gene expression analysis, differential expression, splicing variant detection, and novel transcript discovery, for research institutions and biopharma clients.
• Whole Exome Sequencing (WES) Sequencing service targeting all protein-coding genes in a genome, analyzing germline and somatic variants including SNVs, InDels, CNVs, and SNV filtering with coverage exceeding 80x, offered to research and clinical customers.
• Whole Genome Sequencing (WGS) Comprehensive sequencing of entire genomes using HiSeq X Ten platform for germline variant detection, somatic mutation analysis, and de novo genome assembly, suited to research and clinical applications.
• ATAC Sequencing (ATAC-seq) Epigenomic profiling service for analyzing open chromatin, DNA-binding proteins, and nucleosome positions using Tn5 transposase-based assay with a sensitivity of 50,000 cells minimum, provided to research institutions.
• Single Cell RNA Sequencing (scRNA-seq) High-throughput sequencing service examining nucleic acid sequences from individual cells for cell-type identification and heterogeneous tissue analysis, run on the 10x Chromium Controller platform.
• ChIP Sequencing (ChIP-Seq) Chromatin immunoprecipitation sequencing service for determining DNA-protein interactions and regulatory element mapping with standard and advanced bioinformatics analysis.
• Bioinformatics Services Comprehensive data analysis including QC, alignment, peak calling, variant calling, pathway analysis, and custom bioinformatics pipelines for RNA-seq, WES, WGS, ChIP-seq, ATAC-seq, and Methyl-seq, delivered alongside sequencing services.
• Non-Invasive Prenatal Test (NIPT) CLIA-certified NGS-based prenatal screening service analyzing cell-free fetal DNA from maternal blood for chromosomal aneuploidies (T21, T18, T13) with results delivered in 3-5 business days, available to healthcare providers and patients.
• Full Comprehensive Cancer Panel Hereditary cancer susceptibility testing examining 127 genes associated with cancer syndromes with 99% coverage at 50x, including BRCA1/2, TP53, and Lynch syndrome genes, with 2-3 week turnaround for clinicians and patients.
• NGS-based Liquid Biopsy Blood-based cancer monitoring service detecting circulating tumor cells and cell-free circulating tumor DNA (ctDNA) for real-time tumor progression and treatment effectiveness assessment.
• QuickPathgen Proprietary pathogen detection method combining transcriptome and whole-genome sequencing to identify causative pathogens in unknown diseases through discriminatory sequence analysis.
• FVL (Factor V Leiden) Genotyping Single gene test for Factor V Leiden mutation detection associated with thrombophilia, offered as a CLIA-certified clinical diagnostic.
• 100-QuickPath PCR Arrays Quantitative gene expression profiling arrays focused on cancer hallmarks pathways, analyzing transcription factors and oncogenes across 10 biological capabilities, sold as research-use array kits.
• 100-QuickPath siRNA Arrays Gene silencing screening tool using validated siRNAs targeting drug targets and cancer driver genes for functional studies of gene-gene and gene-drug interactions in cell-based assays, sold as research-use array kits.
• 100-QuickPath Drug Arrays Functional screening platform for drug-drug and drug-gene interaction studies using 66 validated drugs arrayed on 96-well plates targeting apoptosis, cell cycle, kinase signaling, and metabolic pathways, sold as research-use array kits.
• 100-QuickPath Antibody Arrays Protein detection arrays with pre-dispensed antibodies for measuring protein levels of specific genes in pathway-focused studies, sold as research-use array kits.
• Assay Development Services Custom assay development and regulatory affairs support for biopharmaceutical clients, providing end-to-end customization including support for challenging sample types.

Quantifiable outcome

• 99.86-99.97% mapped reads in WES projects
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

One partnership is on record.

• FulgentcoreStrategic or Co-development PartnerQuick Biology collaborates with Fulgent, another sequencing company in Los Angeles, to provide full-scale sequencing service to all clients. This partnership enables expanded service capabilities and capacity for the Southern California market.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/Quick_Biology
• Facebookfacebook.com/quickbiology
• LinkedInlinkedin.com/company/quick-biology-inc.

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quick Biology